<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35974122</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Muscle and skin fibroblast TDP-43 expression, dynamic mutation analysis of NOTCH2NLC and C9orf72 in patients with FOSMN.</ArticleTitle><Pagination><StartPage>6505</StartPage><EndPage>6510</EndPage><MedlinePgn>6505-6510</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-022-06339-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Facial-onset sensory and motor neuronopathy (FOSMN) syndrome is a rare clinical syndrome in which the etiopathogenesis and disease-causing genes remain unknown. In addition, clinical and molecular pathological studies have rarely been evaluated in a large case series.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this study, we present the clinical features and electrodiagnostic findings of the largest cohort of six patients with FOSMN in East Asia to date. Immunofluorescence assessment of TAR DNA-binding protein (TDP)-43 in muscle and skin fibroblasts, detection of GGC trinucleotide repeat expansions in NOTCH2NLC gene, and GGGGCC hexanucleotide repeat expansions in the C9orf72 gene were also performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All patients exhibited typical symptoms and signs of FOSMN syndrome. Almost all patients showed a delayed or absent blink reflex. Neurogenic damage was found in five patients by electromyography. Two of the five patients with muscle and skin biopsies showed TDP-43-positive inclusions in both the nucleus and cytoplasm of muscular tissue and skin fibroblasts. There were no repeat expansions in the C9orf72 or NOTCH2NLC genes in any of the six patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">To date, this is the largest FOSMN cohort in East Asia. TDP-43-positive cytoplasmic inclusions in muscle and skin fibroblasts may be a pathologic feature of the disease. The patient's dynamic mutation test showed no GGC trinucleotide repeat expansions in the NOTCH2NLC and GGGGCC hexanucleotide repeat expansions in the C9orf72 gene. Further studies are needed with more patients.</AbstractText><CopyrightInformation>&#xa9; 2022. Fondazione Societ&#xe0; Italiana di Neurologia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Zhuoting</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chongqing Key Laboratory of Neurology, the First Affiliated Hospital of Chongqing Medical University, 1st Youyi Road, Yuzhong District, Chongqing, 400016, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Guo</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chongqing Key Laboratory of Neurology, the First Affiliated Hospital of Chongqing Medical University, 1st Youyi Road, Yuzhong District, Chongqing, 400016, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The Second Affiliated Hospital of Zunyi Medical University, Intersection of Xinlong Avenue and Xinpu Avenue, Honghuagang District, Zunyi, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Haokun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chongqing Key Laboratory of Neurology, the First Affiliated Hospital of Chongqing Medical University, 1st Youyi Road, Yuzhong District, Chongqing, 400016, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chongqing Key Laboratory of Neurology, the First Affiliated Hospital of Chongqing Medical University, 1st Youyi Road, Yuzhong District, Chongqing, 400016, China. jgire@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Fei</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5981-2922</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Chongqing Key Laboratory of Neurology, the First Affiliated Hospital of Chongqing Medical University, 1st Youyi Road, Yuzhong District, Chongqing, 400016, China. feixiao81@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>W0043</GrantID><Agency>Future Medical Youth Innovation Team of Chongqing Medical University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000720010">NOTCH2NLC protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009132" MajorTopicYN="N">Muscles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">Facial onset sensory and motor neuronopathy syndrome (FOSMN)</Keyword><Keyword MajorTopicYN="N">NOTCH2NLC</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35974122</ArticleId><ArticleId IdType="doi">10.1007/s10072-022-06339-7</ArticleId><ArticleId IdType="pii">10.1007/s10072-022-06339-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vucic S, Tian D, Chong PS, Cudkowicz ME, Hedley-Whyte ET, Cros D (2006) Facial onset sensory and motor neuronopathy (FOSMN syndrome): a novel syndrome in neurology. Brain 129(Pt 12):3384&#x2013;3390</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl258</ArticleId><ArticleId IdType="pubmed">17012296</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer EMJ, Barritt AW, Elamin M, Anderson SJ, Broad R, Nisbet A, Goedee HS, Vazquez Costa JF, Prudlo J, Vedeler CA, Fernandez JP, Panades MP, AlbertiAguilo MA, Bella ED, Lauria G, Pinto W, de Souza PVS, Oliveira ASB, Toro C, van Iersel J, Parson M, Harschnitz O, van den Berg LH, Veldink JH, Al-Chalabi A, Leigh PN, van Es MA (2021) Facial onset sensory and motor neuronopathy: new cases, cognitive changes, and pathophysiology. Neurol Clin Pract 11(2):147&#x2013;157</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000000834</ArticleId><ArticleId IdType="pubmed">33842068</ArticleId><ArticleId IdType="pmc">8032419</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Luo J, Xiao F (2021) Facial numbness, dysarthria, muscle atrophy, and weakness in a young patient. JAMA Neurol 78(10):1273&#x2013;1274</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.2136</ArticleId><ArticleId IdType="pubmed">34251399</ArticleId></ArticleIdList></Reference><Reference><Citation>Im K, Mareninov S, Diaz MFP, Yong WH (1897) An introduction to performing immunofluorescence staining. Methods Mol Biol 2019:299&#x2013;311</Citation></Reference><Reference><Citation>de Boer EMJ, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T, Silsby M, Menon P, van den Bos M, Halliday GM, van den Berg LH, Van Den Bosch L, van Damme P, Kiernan MC, van Es MA, Vucic S (2020) TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry 92(1):86&#x2013;95</Citation></Reference><Reference><Citation>Broad R, Leigh PN (2015) Recognising facial onset sensory motor neuronopathy syndrome: insight from six new cases. Pract Neurol 15(4):293&#x2013;297</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/practneurol-2014-000984</ArticleId><ArticleId IdType="pubmed">25991863</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakis I, Vucic S, Srinivasan J (2014) Facial onset sensory and motor neuronopathy (FOSMN) of childhood onset. Muscle Nerve 50(4):614&#x2013;615</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24299</ArticleId><ArticleId IdType="pubmed">24862832</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Q, Chu L, Tan L, Zhang H (2016) Facial onset sensory and motor neuronopathy. Neurol Sci 37(12):1905&#x2013;1909</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-016-2686-7</ArticleId><ArticleId IdType="pubmed">27473302</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Huang Q, Xuan Z, Wu S, Zhao Y, Xu H (2020) Facial-onset sensory motor neuronopathy syndrome is not always facial onset. J Clin Neurol 16(4):729&#x2013;730</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2020.16.4.729</ArticleId><ArticleId IdType="pubmed">33029990</ArticleId><ArticleId IdType="pmc">7541974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohashi N, Nonami J, Kodaira M, Yoshida K, Sekijima Y (2020) Taste disorder in facial onset sensory and motor neuronopathy: a case report. BMC Neurol 20(1):71</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-020-01639-x</ArticleId><ArticleId IdType="pubmed">32113480</ArticleId><ArticleId IdType="pmc">7049225</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Cao B, Chen Y, Liang Y, Wei Q, Zhou D, Shang H (2019) Facial onset motor and sensory neuronopathy syndrome with a novel TARDBP mutation. Neurologist 24(1):22&#x2013;25</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NRL.0000000000000201</ArticleId><ArticleId IdType="pubmed">30586030</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano N, Catalani A, Lattante S, Belardo A, Proietti S, Bertini L, Silvestri F, Catalani E, Cervia D, Zolla L, Sabatelli M, Welshhans K, Ceci M (2020) ALS skin fibroblasts reveal oxidative stress and ERK1/2-mediated cytoplasmic localization of TDP-43. Cell Signal 70:109591</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2020.109591</ArticleId><ArticleId IdType="pubmed">32126264</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhou S, Ding X, Ma M, Zhang J, Zhou Y, Wu E, Teng J (2015) Activation of ER stress and autophagy induced by TDP-43 A315T as pathogenic mechanism and the corresponding histological changes in skin as potential biomarker for ALS with the mutation. Int J Biol Sci 11(10):1140&#x2013;1149</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.12657</ArticleId><ArticleId IdType="pubmed">26327808</ArticleId><ArticleId IdType="pmc">4551750</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossor AM, Jaunmuktane Z, Rossor MN, Hoti G, Reilly MM (2019) TDP43 pathology in the brain, spinal cord, and dorsal root ganglia of a patient with FOSMN. Neurology 92(9):e951&#x2013;e956</Citation><ArticleIdList><ArticleId IdType="pubmed">30700593</ArticleId><ArticleId IdType="pmc">6404468</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonoda K, Sasaki K, Tateishi T, Yamasaki R, Hayashi S, Sakae N, Ohyagi Y, Iwaki T, Kira J (2013) TAR DNA-binding protein 43 pathology in a case clinically diagnosed with facial-onset sensory and motor neuronopathy syndrome: an autopsied case report and a review of the literature. J Neurol Sci 332(1&#x2013;2):148&#x2013;153</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2013.06.027</ArticleId><ArticleId IdType="pubmed">23849263</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang XR, Tang BS, Jin P, Guo JF (2022) The phenotypes and mechanisms of NOTCH2NLC-related GGC repeat expansion disorders: a comprehensive review. Mol Neurobiol 59(1):523&#x2013;534</Citation></Reference><Reference><Citation>Deng J, Gu M, Miao Y, Yao S, Zhu M, Fang P, Yu X, Li P, Su Y, Huang J, Zhang J, Yu J, Li F, Bai J, Sun W, Huang Y, Yuan Y, Hong D, Wang Z (2019) Long-read sequencing identified repeat expansions in the 5&#x2032;UTR of the NOTCH2NLC gene from Chinese patients with neuronal intranuclear inclusion disease. J Med Genet 56(11):758&#x2013;764</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2019-106268</ArticleId><ArticleId IdType="pubmed">31413119</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>